Interleukin‐6 (IL‐6) is an important cytokine for EMT and tumour metastasis of NSCLC.11, 12, 13 The increase of IL‐6 can cause the resistance to molecular targeted therapy in lung cancer,14, 15, 16 and circulating IL‐6 level may be a prognostic marker for patients with NSCLC.17 Moreover, a humanized anti‐IL‐6 antibody (ALD518) has been used to treat NSCLC.18 Our previous studies showed that IL‐6 could induce TIM‐4 expression in vitro.10 Here, we investigated the exact role of TIM‐4 in IL‐6‐induced NSCLC migration, invasion and EMT. Here, TIMD4 is linked to lung carcinoma.